Robot-assisted post-chemotherapy retroperitoneal lymph node dissection for metastatic non-seminomatous germ cell tumors using two distinct surgical approaches: A tertiary care experience

采用两种不同的手术入路,机器人辅助行化疗后腹膜后淋巴结清扫术治疗转移性非精原细胞瘤:三级医疗机构的经验

阅读:3

Abstract

OBJECTIVE: Robot-assisted post-chemotherapy retroperitoneal lymph node dissection (R-PC-RPLND) is increasingly used as an alternative to open surgery for metastatic testicular cancer. This study aimed to summarize the experience with lateral and supine approaches in R-PC-RPLND for metastatic non-seminomatous germ cell tumors, applied based on different clinical indications. METHODS: We conducted a retrospective analysis of 42 consecutive patients who underwent R-PC-RPLND at our tertiary cancer center from May 2016 to July 2023. Patients were categorized based on the surgical approach used: lateral position (28 patients) or supine position (14 patients). Data on perioperative outcomes, complications, and oncological efficacy were assessed and reported using descriptive statistics. RESULTS: The median patient age was 28.0 (interquartile range [IQR]: 23.5-30.5) years, and the median body mass index was 22.7 (IQR: 19.9-24.2) kg/m(2). The median operative time was 167.5 (IQR: 135.0-216.0) min, and the median estimated blood loss was 100.0 (IQR: 50.0-200.0) mL. Vascular injuries occurred in 4.8% of the cases, with no conversions to open surgery required. Postoperative complications were observed in 14% of the patients, all classified as Clavien-Dindo grades I-II. Histopathological examination revealed necrosis or fibrosis in 43% of the cases, teratoma in 31%, and viable germ cell tumor in 26%. During a median follow-up of 22.0 (IQR: 16.0-30.5) months, 17% of the patients experienced relapse, with a median time to relapse of 5.0 (IQR: 4.0-7.0) months. CONCLUSION: Both lateral and supine approaches for R-PC-RPLND demonstrated favorable surgical and oncological outcomes, with acceptable operative times, minimal blood loss, low complication rates, and effective oncological control. The choice between these approaches should consider patient-specific factors and surgeon expertise, allowing for tailored treatment that optimizes outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。